Nanotein Technologies adds to its best-in-class NanoSpark™ reagent line, with the launch of NanoSpark™ GROW-NK, a high-performance reagent for the ex vivo activation and expansion of Natural Killer cells, in an easy-to-use, feeder cell free format.

“We are pleased to accept this award and collaboration with the U.S. Government to ensure that, as a society, we are better prepared for the next pandemic. This award validates our unique approach of combining antibody development and electrochemical-based diagnostics for a rapid response to save lives and manage infectious disease outbreaks,” stated Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.

Greg Merril, co-Founder and CEO of Adaptive Phage Therapeutics: “This investment will allow us to advance our lead clinical programs related to musculoskeletal infections, including prosthetic joint infections and diabetic foot osteomyelitis.”

“With the option for subcutaneous self-administration, crovalimab could help meet the lifelong needs of people living with PNH and their caregivers,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Genetech Global Product Development. “Data from the COMMODORE studies will be submitted to regulatory authorities around the world.”

In this project, which will be carried out over three years with a total budget of about $3.6 million($2.8 million in government support), Dx&Vx will lead the development as a lead company.